Novo Nordisk shares plunge as obesity drug trails Eli Lilly in head to head trial

Novo Nordisk shares fell Monday after its drug CagriSema trailed Eli Lilly's tirzepatide in a trial. The drug achieved slightly less weight loss than its rival.

Novo Nordisk announced on Monday that its experimental obesity treatment CagriSema failed to meet the primary endpoint in a clinical trial designed to show the drug was non-inferior to Eli Lilly’s tirzepatide. Following the public announcement, shares in the company based in Denmark DKDK fell by approximately 8% by 09:46 GMT on February 23, 2026.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on December 3, 2025. REUTERS/Tom Little//File Photo
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on December 3, 2025. REUTERS/Tom Little//File Photo